Seattle, WA—Choosing when to start regular breast cancer screening is a complicated decision for individual women and their providers. For most women, increasing age is the biggest risk factor for breast cancer, which is much more common at age 60 than at 40. But two new articles on other risk factors may inform guidelines and clinical practice about screening mammography from age 40 to 49.
The articles in the May 1 Annals of Internal Medicine provide information on how certain risk factors affect breast cancer risk and shift the balance between harms and benefits. Screening harms include false-positive results that can lead to invasive follow-up procedures and overdiagnosis, which prompts unnecessary treatment. Screening has a less favorable balance between benefits and harms in average-risk women in their 40s than in women aged 50 to 74.
This research addresses the need for more information about screening women in their 40s—a need highlighted by the U.S. Preventive Services Task Force’s updated breast cancer screening guidelines in 2009. Also published in the Annals of Internal Medicine, these guidelines advise screening mammography every two years for women aged 50 to 74. The guidelines recommend that women in their 40s consider their personal values regarding the benefits and harms and then decide when to begin regular screening.
Group Health Research Institute Senior Investigators Diana Miglioretti, PhD, and Diana Buist, PhD, contributed to both of the new Annals articles. Together, the companion articles estimate that the benefits and harms of getting screening mammograms every two years are the same for groups of women aged 40–49 who have a twofold increased risk level of breast cancer as for groups of women aged 50–74 with an average breast cancer risk level. Factors that increase 40- to 49-year-old women’s risk by twofold are having a first-degree relative (parent, sibling, or child) with breast cancer, or having extremely dense breast tissue (as seen on a mammogram).
“Mainly, we wanted to find out the tipping point: what level of increased risk women in their 40s needed to have to reach the same benefit-to-harm ratio for screening mammography as women aged 50 to 74,” said Dr. Miglioretti. The international research team used data from the Breast Cancer Surveillance Consortium (BCSC), a U.S. research network of mammography registries. The BCSC is the nation’s largest longitudinal collection of breast imaging data, covering 9.5 million mammograms, 2.3 million women, and 114,000 breast cancer cases so far. By continuously collecting information on breast cancer screening, risk factors, and cancer outcomes, the BCSC provides long-term data on screening as it occurs in everyday clinical practice to help answer preventive health care questions.
In one article, Nicolien van Ravesteyn, MSc, Jeanne Mandelblatt, MD, MPH, and colleagues including Drs. Miglioretti and Buist identified the threshold of risk needed for women ages 40–49 to have comparable benefits and harms as seen when average-risk women aged 50–74 are screened every other year using mammography. They used four independent well-established simulation models that are part of the National Cancer Institute’s Cancer Intervention and Surveillance Modeling Network (CISNET) collaborative. Ms. van Ravesteyn is a researcher at Erasmus Medical Center in Rotterdam, The Netherlands; and Dr. Mandelblatt is the associate director for population sciences at Georgetown University Medical Center’s Lombardi Comprehensive Cancer Center in Washington, DC.
To estimate the benefits and harms of mammography screening for women in their 40s, the CISNET models used BCSC and other information on large populations of U.S. women. The results indicated that the benefits and harms from screening mammograms every two years for women 40-49 with a twofold increase in breast cancer risk are similar to those for average-risk women who start biennial screening at age 50. For annual screening, a fourfold increased risk level is where the benefits outweigh the harms for starting screening at age 40. There were only small differences in benefits using digital compared to plain-film mammography, but digital screening generates many more false-positive results than does plain film.
“Our population models show what can be expected across populations with different risk levels,” Dr. Mandelblatt said. “The models cannot determine outcomes for individual women. Policymakers can use them to inform guidelines for populations.”
The first author of the other article is Heidi D. Nelson, MD, MPH, an investigator at the Oregon Evidence-based Practice Center and the Knight Cancer Institute at Oregon Health & Science University and Providence Cancer Center in Portland. With Drs. Buist and Miglioretti and colleagues including Ellen O’Meara, PhD,a research associate at Group Health Research Institute, Dr. Nelson conducted a meta-analysis—a rigorous review of previous studies—from 66 publications selected for their relevance and quality. They also conducted new analyses using BCSC data on more than 380,000 women who were 40–49 when they had a screening mammogram from 1994 to 2010, to see how family history and other risk factors affected breast cancer risk for women in their 40s.
“Most of the risk factors that we considered did not increase breast cancer risk,” Dr. Nelson said. Other potential risk factors that they evaluated—such as race/ethnicity, body mass index, physical activity, and using alcohol, tobacco, or hormone therapy—had effects that were either small, undetectable, or equivocal. “Our results indicate that we can focus on just a few significant risk factors to simplify approaches to risk-based screening for women in their 40s,” she added.
The research in the two articles was possible because three national research groups—BCSC, CISNET, and the Evidence-based Practice Center—joined forces. Each contributed unique strengths: extensive data, comprehensive breast cancer models, and data interpretation. The U.S. Preventive Services Task Force previously used information from the three groups to develop its current breast cancer screening recommendations.
In an accompanying editorial, Otis Webb Brawley, MD, chief medical officer and executive vice president of the American Cancer Society and author of the book How We Harm, referred to the BCSC and CISNET as “national treasures.”
The authors called for additional research based on the findings, to see how well these risk estimates, which are based on large numbers of women, predict risks for individual women. In the meantime, said Dr. Buist, “taken together, the results from these articles provide strong evidence that professional groups can use to refine screening guidelines.”
Funding was from the National Cancer Institute. The collaboration between BCSC, CISNET, and the Evidence-based Practice Center was supported in part by the 2009 American Recovery and Reinvestment Act (ARRA) and by the National Cancer Institute, which recently awarded a $20 million National Cancer Institute Program Project grant, co-led by Dr. Miglioretti, to the BCSC.
Ms. van Ravesteyn and Drs. Mandelblatt, Nelson, Buist, Miglioretti, and O’Meara’s collaborators were Bernadette Zakher, MBBS, Amy Cantor, MD, MPH, Rongwei Fu, PhD, and Jessica Griffin, MS, of the Oregon Evidence-based Practice Center, Oregon Health & Science University, in Portland; Eveline A.M. Heijnsdijk, PhD, and Harry J. de Koning, MD, PhD, of Erasmus MC, in Rotterdam, The Netherlands; Karla Kerlikowske, MD, MS, of the University of California San Francisco; Amy Trentham-Dietz, PhD, and Oguzhan Alagoz, PhD, of the University of Wisconsin, Madison; Natasha K. Stout, PhD, of Harvard Medical School in Boston; Sandra J. Lee, DSc, and Hui Huang, MS, of Dana-Farber Cancer Institute in Boston; Clyde B. Schechter, MD, MA, of Albert Einstein College of Medicine in New York; and Aimee M. Near, MPH, of Georgetown University Medical Center and Lombardi Comprehensive Cancer Center in Washington DC.
The Breast Cancer Surveillance Consortium (BCSC) is the nation's largest and most comprehensive collection of breast cancer screening information. It's a research resource for studies designed to assess the delivery and quality of breast cancer screening and related patient outcomes in the United States. The BCSC is a National Cancer Institute-funded collaborative network of seven mammography registries with linkages to tumor and/or pathology registries. The network is supported by a central Statistical Coordinating Center. Currently, the Consortium's database contains information on over 9.5 million mammographic examinations, 2.3 million women, and 114,000 breast cancer cases (95,000 invasive cancers and 19,000 ductal carcinoma in situ). More information: http://breastscreening.cancer.gov.
The Cancer Intervention and Surveillance Modeling Network (CISNET) is a consortium of NCI-sponsored investigators that use statistical modeling to improve our understanding of cancer control interventions in prevention, screening, and treatment and their effects on population trends in incidence and mortality. These models can be used to guide public health research and priorities. More information: http://cisnet.cancer.gov.
The Oregon Evidence-based Practice Center (Oregon EPC) conducts systematic reviews of health care topics for federal and state agencies and private foundations. These reviews report the evidence from clinical research studies and the quality of that evidence for use by policymakers in decisions on guidelines and coverage. The Center is one of 14 EPCs sponsored by the Agency for Healthcare Research and Quality (AHRQ). More information: www.ohsu.edu/xd/research/centers-institutes/evidence-based-practice-center/.
Kaiser Permanente is committed to helping shape the future of health care. We are recognized as one of America’s leading health care providers and not-for-profit health plans. Founded in 1945, Kaiser Permanente has a mission to provide high-quality, affordable health care services and to improve the health of our members and the communities we serve. We currently serve more than 12.4 million members in eight states and the District of Columbia. Care for members and patients is focused on their total health and guided by their personal Permanente Medical Group physicians, specialists and team of caregivers. Our expert and caring medical teams are empowered and supported by industry-leading technology advances and tools for health promotion, disease prevention, state-of-the-art care delivery and world-class chronic disease management. Kaiser Permanente is dedicated to care innovations, clinical research, health education and the support of community health. For more information, go to: kp.org/share.